Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients

Journal of Steroid Biochemistry and Molecular Biology

Volumn 63, Issue 1-3, 1997, Pages 53-58

  Geisler, Jürgen ^a   Lien, Ernst Asbjørn ^a   Ekse, Dagfinn ^a   Lønning, Per Eystein ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; ESTROGEN; ESTRONE; ESTRONE SULFATE; PRASTERONE; PRASTERONE SULFATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN BLOOD LEVEL; ESTROGEN SYNTHESIS; FEMALE; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; PLASMA CLEARANCE; POSTMENOPAUSE; RADIOIMMUNOASSAY;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; DEHYDROEPIANDROSTERONE SULFATE; ENZYME INHIBITORS; ESTRONE; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTMENOPAUSE; RADIOIMMUNOASSAY;

EID: 0344878875     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(97)00071-X     Document Type: Article

References (37)

1. Grodin J. M., Siiteri P. K. and MacDonald P. C., Source of estrogen production in postmenopausal women. Journal of Clinical Endocrinology Mand Metabolism 36 (1973) 207-214.
2. Murray M., Cantrill E. and Farrell G. C., Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide. Journal of Pharmacology and Experimental Therapeutics 265 (1993) 477-481.
3. Lønning P. E., Kvinnsland S., Thorsen T. and Ueland P. M., Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. Clinical Pharmacokinetics 13 (1987) 393-406.
4. Lanning P. E. and Skulstad P., Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide. Journal of Steroid Biochemistry 33 (1989) 565-571.
5. Bolt H. M., Metabolism of estrogens - natural and synthetic. Pharmacological Therapeutics 4 (1979) 155-181.
6. Lønning P. E., Johannessen D. C., Thorsen T. and Ekse D., Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition. Journal of Steroid Biochemistry 33 (1989) 541-545.
7. Pasqualini J. R., Chetrite G., Nguyen B.-L., Maloche C., Delalonde L., Talbi M., Feinstein M.-C., Blacker C., Botella J. Paris J., Estrone sulfate-sulfatase and 17β-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. Journal of Steroid Biochemistry and Molecular Biology 53 (1995) 407-412.
8. Santner S. J., Feil P. D. and Santen R. J., In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. Journal of Clinical Endocrinology and Metabolism 59 (1984) 29-33.
9. Lønning P. E., Johannessen D. C. and Thorsen T., Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. British Journal of Cancer 60 (1989) 107-111.
10. MacNeill F. A., Jones A. L., Jacobs S., Lønning P. E., Powles T. J. and Dowsett M., The influence of aminoglutethimide and analogue rogletimide on peripheral aromatisation in breast cancer. British Journal of Cancer 66 (1992) 692-697.
11. Lønning P. E. and Ekse D., A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology 55 (1995) 409-412.
12. Stuart-Harris R., Dowsett M., D'Souza A., Donaldson A., Harris A. L., Jeffcoate S. L. and Smith I. E., Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. Clinical Endocrinology 22 (1985) 219-226.
13. Santen R. and Samojlik E., Medical adrenalectomy for treatment of metastatic breast carcinoma. Breast Cancer - Advances in Research and Treatment 3 (1979) 79-115.
14. Samojlik E. and Santen R. J., Adrenal suppression with aminoglutethimide. III. Comparison of plasma steroids in postmenopausal women treated for breast carcinoma. Journal of Clinical Endocrinology and Metabolism 47 (1978) 717-724.
15. Dowsett M., Goss P. E., Powles T. J., Hutchinson G., Brodie A. M. H., Jeffcoate S. L. and Coombes R. C., Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Research 47 (1987) 1957-1961.
16. Lenning P. E., Helle S. I., Johannessen D. C., Adlercreutz H., Lien E. A., Tally M., Ekse D., Fotsis T., Anker G. B. and Hall K., Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clinical Endocrinology 42 (1995) 23-30.
17. Schanche J.-S., Lønning P. E., Ueland P. M. and Kvinnsland S., Determination of aminoglutethimide and N-acetylaminoglutethimide in human plasma by reversed-phase liquid chromatography. Therapeutic Drug Monitoring 6 (1984) 221-226.
18. Santen R. J., Santner S., Davis B., Veldhuis J., Samojlik E. and Ruby E., Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. Journal of Clinical Endocrinology and Metabolism 47 (1978) 1257-1265.
19. Jones A. L., MacNeill F., Jacobs S., Lønning P. E., Dowsett M. and Powles T. J., The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. European Journal of Cancer 28A (1992) 1712-1716.
20. Lønning P. E., Jacobs S., Jones A., Haynes B., Powles T. and Dowsett M., The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. British Journal of Cancer 63 (1991) 789-793.
21. Lønning P. E. and Lien E., Mechanisms of action of endocrine treatment in breast cancer. Critical Reviews in Oncology/ Haematology 21 (1995) 158-193.
22. Samojlik E., Santen R. J. and Worgul T. J., Plasma estrone-sulfate assessment of reduced estrogen production during treatment of metastatic breast cancer. Steroids 39 (1982) 497-507.
23. Lønning P. E. and Kvinnsland S., Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 35 (1988) 685-710.
24. Longcope C. and Williams K. I. H., The metabolism of estrogens in normal women after pulse injections of 'H-estradiol and 'H-estrone. Journal of Clinical Endocrinology and Metabolism 38 (1974) 602-607.
25. Longcope C., The metabolism of estrone sulfate in normal males. Journal of Clinical Endocrinology 34 (1972) 113-122.
26. Wilkinson G. R. and Shand D. G., Commentary: a physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics 18 (1975) 377-390.
27. Barrett-Connor E., Khaw K. T. and Yen S. S. C., A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. New England Journal of Medicine 315 (1986) 1519-1524.
28. Helzlsouer K. J., Gordon G. B., Alberg A. J., Bush T. L. and Comstock G., Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Research 52 (1992) 1-4.
29. Vermeulen A., Paridaens R. and Heusen J. C., Effects of aminoglutethimide on adrenal steroid secretion. Clinical Endocrinology 19 (1983) 673-682.
30. Harris A. L., Dowsett M., Smith I. E. and Jeffcoate S. L., Endocrine effects of low dose aminoglutethimide alone in advanced breast cancer. British Journal of Cancer 47 (1983) 621-627.
31. Harris A. L., Dowsett M., Smith I. E. and Jeffcoate S., Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. European Journal of Clinical Oncology 20 (1984) 463-469.
32. Fehér T. and Halmy L., A comparative study of dehydroepiandrosterone and dehydroepiandrosterone sulphate dynamics by the 'urinary' and 'blood approach' under physiological conditions. Acta Endocrinologica 75 (1974) 314-424.
33. Geisler J., Engelsen B., Berntsen H., Geisler S. and Lønning P. E., Differential influence of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehy drocpiandrostcronc sulphate in male epileptic patients. Journal of Endocrinology 153 (1997) 307-312.
34. Conney A. H. and Klutch A., Increased activity of androgen hydroxylases in liver microsomes of rats treated with phenobarbital and other drums. Journal of Biological Chemistry 238 (1963) 1611-1617.
35. Kawano J., Kotani T., Ohtaki S., Minamino N., Matsuo H., Oinuma T. and Aikawa E., Characterization of rat and human steroid sulphates. Biochimica et Biophysica Acta 997 (1989) 199-205.
36. Purohit A., Dauvois S., Parker M. G., Potter B. V. L., Williams G. J. and Reed M. J., The hydrolysis of oestrone sulphate and dehydroepiandrosterone sulphate by human steroid sulphatase expressed in transfected COS-1 cells. Journal of Steroid Biochemistry and Molecular Biology 50 (1994) 101-104.
37. Purohit A., Williams G. J., Roberts C. J., Potter B. V. L. and Reed M. J., In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. International Journal of Cancer 63 (1995) 106-111.